Agentic AI market projected by 2030, up from $7.8B today — industry analysts
of enterprise applications will embed AI agents by end of 2026 — Gartner prediction
of organizations actively using agents in production, vs 79% claiming adoption — the real gap
The generative AI experimentation phase is drawing to a close. What is emerging in its place is a structural shift in how enterprises deploy intelligence at scale — systems that don't just respond to prompts but can reason, plan, and pursue complex multi-step goals autonomously. Yet the gap between hype and production is stark: while 62% of companies are experimenting, most have not scaled agents enterprise-wide. 2026 is the inflection point where early architectural decisions will determine which organizations lead and which stay stuck in pilot purgatory.
→Hatteras Venture Partners raised $200M across two 2025 funds with 100+ portfolio companies; invested in Duke-affiliated AI drug discovery startup Ten63 Therapeutics
→Alexandria LaunchLabs at RTP provides lab infrastructure and seed capital; Cape Fear BioCapital and NovaQuest Capital active at seed and growth stages
→IDEA Fund Partners (Durham), Bull City Venture Partners, and Excelerate Health Ventures all active with strong university spinout pipelines